BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Change in Directorate
We would like to inform the exchanges that Dr.C.V Srinivas ( DIN# 04495304) Independent Director of the Company has completed his tenure of five years as Independent Director of the Company and he ceases to be on the Board of the Company w.e.f 28.06.2024. BAL PHARMA LTD. - 524824 - Closure of Trading Window
Trading Window of the Company on designated persons and their immediate relatives will be closed from 1st July 2024 until 48 hours of declaration of the Un Audited financial results for the quarter ended 30.06.2024. BAL PHARMA LTD. - 524824 - Disclosure under Regulation 30A of LODR
Disclosure as per Regulation 31 A of SEBI (LODR) Regulations- Intimation reg receipt of applications from promoters for reclassification of their shareholding in the Company as Public holding. BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance with Regulation 47 of SEBI(LODR) Regulations, we are submitting the newspaper advertisements of the abridged Audited standalone and consolidated financial results of the company for the quarter and year ended 31.03.2024 announced by the Company on 28.05.2024 and published in Financial Express ( English) and Snajayvani ( Kannada ) on 29.05.2024. BAL PHARMA LTD. - 524824 - Corporate Action-Board approves Dividend
Board of Directors of the Company at their meeting held on 28.05.2024 has recommended payment of Dividend of Re.1.20 paise per equity share of Rs.10 each i.e 12%, which is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting . BAL PHARMA LTD. - 524824 - Audited Financial Results 31.03.2024
Audited stand alone & Consolidated financial results for the quarter and financial year ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors. BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting
Board of Directors of the Company has met today and inter alia transacted the following business, 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM. 2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25. BAL PHARMA LTD. - 524824 - Compliances-Reg.24(A)-Annual Secretarial Compliance
We are submitting the Annual Secretarial Compliance report duly certificated by the practicing Company Secretary for the financial year ended 31.03.2024. BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation reg loss of Share Certificate BAL PHARMA LTD. - 524824 - Corporate Action-Board to consider Dividend
Please refer to our intimation regarding Board Meeting dated 30.04.2024.